Ameriprise
TRIB

Ameriprise’s Trinity Biotech TRIB Stock Holding History

Ameriprise’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-143
Closed -$13K – 4359
2014
Q3 		$13K Sell
143
-5
-3% -$541 ﹤0.01% 4709
2014
Q2 		$17K Sell
148
-54
-27% -$6.4K ﹤0.01% 4418
2014
Q1 		$24K Hold
202
– – ﹤0.01% 4119
2013
Q4 		$25K Buy
202
+60
+42% +$7.2K ﹤0.01% 3965
2013
Q3 		$15K Sell
142
-2
-1% -$195 ﹤0.01% 4620
2013
Q2 		$12K Buy
+144
New +$11.9K ﹤0.01% 4652

Other funds holding TRIB

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
TAM
THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return
AAM
ACK Asset Management Greenwich, Connecticut $801M AUM 60.42% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
CAM
Cortina Asset Management Milwaukee, Wisconsin $1.62B AUM 15.44% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return

Ameriprise's TRIB Position: Q4 2014 in Review

Ameriprise sold out of Trinity Biotech (TRIB) in Q4 2014, closing a stake of 143 shares — an estimated $13K sold.

Ameriprise first reported a position in TRIB in Q2 2013 and held it in 6 quarters. The position peaked at $25K in Q4 2013. 92 funds tracked by Wall St. Rank hold TRIB as of Q4 2014.

  • Ameriprise reported no remaining Trinity Biotech position as of Q4 2014 after selling out during the quarter.
  • Ameriprise sold 143 Trinity Biotech shares in Q4 2014, an estimated $13K.
  • Ameriprise first reported a position in Trinity Biotech in Q2 2013 and held it in 6 quarters.
  • Ameriprise's Trinity Biotech position peaked at $25K in Q4 2013.
  • 92 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2014.

Based on Ameriprise's 13F filing for Q4 2014, filed 13 Feb 2015.